In light of the mechanistic synergies between RT and fulvestrant to favorably immunomodulate the TME shown here and the clear clinical safety record of concurrent adjuvant and palliative RT with systemic anti-estrogens, our studies strongly support revisiting this combination along with ICIs in the large numbers of patients with advanced anti-estrogen resistant ER+ breast cancer. Here, ESR1 is linked to breast carcinoma.